by Gilles Rubinstenn | May 29, 2023 | News
ReST Therapeutics announces that Pr. John Krystal has joined its Scientific Advisory Board ReST Therapeutics, clinical-stage biotech company developing breakthrough therapies to treat Alzheimer Disease (AD) and Post-Traumatic Stress Disorder (PTSD), today announced...
by Gilles Rubinstenn | Feb 23, 2023 | News
ReST Therapeutics announces the endorsement by the European Medicine Agency (EMA) to enter the clinical phase and request First in Human (FIH) administration of its drug candidate FENM. ReST Therapeutics, clinical-stage biotech company developing breakthrough...
by Gilles Rubinstenn | Nov 7, 2022 | News
On October 11, 2022, the USPTO issued ReST Therapeutics a patent on the use of its drug candidate FENM for the treatment of anxiety and PTSD. ReST Therapeutics’ project is to develop a proprietary drug candidate for the treatment of Post-Traumatic Syndrome and...
by Gilles Rubinstenn | Jun 15, 2022 | News
On May 6, the National Institute of Intellectual Property (INPI) issued ReST Therapeutics and its academic co-owners (University of Montpellier, INSERM, and the Ecole Pratique des Hautes Etudes) a patent on neuroprotection. ReST Therapeutics’ project is to...
by Gilles Rubinstenn | Jul 22, 2021 | News
Biological Psychiatry Published: May 09, 2021DOI: https://doi.org/10.1016/j.biopsych.2021.04.024 Fluoroethylnormemantine, a Novel NMDA Receptor Antagonist, for the Prevention and Treatment of Stress-Induced Maladaptive Behavior. Briana K.Chen, Victor M.Luna, Margaret...
by Gilles Rubinstenn | Jul 22, 2021 | News
International Journal of Neuropsychopharmacology, 2021 Jul 14;24(6):519-531. https://doi.org/10.1093/ijnp/pyab007 Fluoroethylnormemantine, A Novel Derivative of Memantine, Facilitates Extinction Learning WithoutSensorimotor Deficits. Briana K. Chen, Gwenaëlle Le Pen,...
